File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Effect of Sandostatin® LAR® on sleep apnoea in acromegaly: Correlation with computerized tomographic cephalometry and hormonal activity

TitleEffect of Sandostatin® LAR® on sleep apnoea in acromegaly: Correlation with computerized tomographic cephalometry and hormonal activity
Authors
Issue Date2001
PublisherWiley-Blackwell Publishing Ltd.. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=0300-0664
Citation
Clinical Endocrinology, 2001, v. 55 n. 4, p. 477-483 How to Cite?
AbstractOBJECTIVES: Sleep apnoea has been reported to occur in subjects with acromegaly. This study evaluates the relationship among biochemical activity, sleep apnoeic activity and upper airway anatomic profile in acromegaly, and the effect of Sandostatin® LAR®, a long-acting somatostatin analogue, on these parameters. PATIENTS: Fourteen subjects with acromegaly were recruited. MEASUREMENTS: Subjects were assessed at baseline and those with apnoea-hypopnoea index (AHI)≥5 were reassessed after 6 months of treatment with Sandostatin® LAR® 20-30 mg IMI 4-weekly. Biochemical activity was assessed with levels of GH and IGF-1. Sleep disordered breathing was assessed with overnight polysomnography. Upper airway anatomic profile was defined with computerized tomographic cephalometry. RESULTS: Of 14 subjects (age 42.0±8.1 years, mean ±SD; 11 men) at baseline, there was a positive correlation between GH and tongue length (VT; P=0.004), and between AHI and cephalometric indices: length of soft palate (PMU; P=0.002); mandibular plane-hyoid bone distance (MPH; P=0.017), maximum thickness of soft palate (Max-SP; P=0.018)and VT (P=0.027). Eight patients had sleep disordered breathing (AHI≥5) which was predominantly obstructive in nature (AHI=29.4±22.6). After treatment, there were significant improvements in hormonal profile: GH, mU/l (before, 51.5±27.8; after, 8.0±7.4; P=0.017) and IGF-1, nmol/l (before, 95.5±23.4; after, 35.0±12.4; P=0.012); sleep-disordered breathing: AHI (before, 29.4±22.6; after, 13.4±11.12; P=0.025), snoring episodes (before, 486±240; after, 165±170; P=0.05); cephalometric indices, mm: MPH (before, 18.8±12.1; after, 14.8±8.4; P=0.018), VT (before, 72.3±4.4; after, 69.7±4.3; P=0.05). There was a positive correlation between the reduction in GH and AHI (r=0.738, P=0.037). CONCLUSIONS: The findings demonstrated that there was correlation between sleep apnoea severity and soft tissue overgrowth at the upper airway region in acromegaly. They also suggest that Sandostatin® LAR® improved obstructive sleep apnoea in acromegaly, and the effect might be partly mediated via a reduction in upper airway soft tissue, in particular that of the tongue, concomitant with a reduction in GH levels.
Persistent Identifierhttp://hdl.handle.net/10722/162466
ISSN
2015 Impact Factor: 3.487
2015 SCImago Journal Rankings: 1.314
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorIp, MSMen_US
dc.contributor.authorTan, KCBen_US
dc.contributor.authorPeh, WCGen_US
dc.contributor.authorLam, KSLen_US
dc.date.accessioned2012-09-05T05:20:13Z-
dc.date.available2012-09-05T05:20:13Z-
dc.date.issued2001en_US
dc.identifier.citationClinical Endocrinology, 2001, v. 55 n. 4, p. 477-483en_US
dc.identifier.issn0300-0664en_US
dc.identifier.urihttp://hdl.handle.net/10722/162466-
dc.description.abstractOBJECTIVES: Sleep apnoea has been reported to occur in subjects with acromegaly. This study evaluates the relationship among biochemical activity, sleep apnoeic activity and upper airway anatomic profile in acromegaly, and the effect of Sandostatin® LAR®, a long-acting somatostatin analogue, on these parameters. PATIENTS: Fourteen subjects with acromegaly were recruited. MEASUREMENTS: Subjects were assessed at baseline and those with apnoea-hypopnoea index (AHI)≥5 were reassessed after 6 months of treatment with Sandostatin® LAR® 20-30 mg IMI 4-weekly. Biochemical activity was assessed with levels of GH and IGF-1. Sleep disordered breathing was assessed with overnight polysomnography. Upper airway anatomic profile was defined with computerized tomographic cephalometry. RESULTS: Of 14 subjects (age 42.0±8.1 years, mean ±SD; 11 men) at baseline, there was a positive correlation between GH and tongue length (VT; P=0.004), and between AHI and cephalometric indices: length of soft palate (PMU; P=0.002); mandibular plane-hyoid bone distance (MPH; P=0.017), maximum thickness of soft palate (Max-SP; P=0.018)and VT (P=0.027). Eight patients had sleep disordered breathing (AHI≥5) which was predominantly obstructive in nature (AHI=29.4±22.6). After treatment, there were significant improvements in hormonal profile: GH, mU/l (before, 51.5±27.8; after, 8.0±7.4; P=0.017) and IGF-1, nmol/l (before, 95.5±23.4; after, 35.0±12.4; P=0.012); sleep-disordered breathing: AHI (before, 29.4±22.6; after, 13.4±11.12; P=0.025), snoring episodes (before, 486±240; after, 165±170; P=0.05); cephalometric indices, mm: MPH (before, 18.8±12.1; after, 14.8±8.4; P=0.018), VT (before, 72.3±4.4; after, 69.7±4.3; P=0.05). There was a positive correlation between the reduction in GH and AHI (r=0.738, P=0.037). CONCLUSIONS: The findings demonstrated that there was correlation between sleep apnoea severity and soft tissue overgrowth at the upper airway region in acromegaly. They also suggest that Sandostatin® LAR® improved obstructive sleep apnoea in acromegaly, and the effect might be partly mediated via a reduction in upper airway soft tissue, in particular that of the tongue, concomitant with a reduction in GH levels.en_US
dc.languageengen_US
dc.publisherWiley-Blackwell Publishing Ltd.. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=0300-0664en_US
dc.relation.ispartofClinical Endocrinologyen_US
dc.rightsClinical Endocrinology. Copyright © Blackwell Publishing Ltd.-
dc.subject.meshAcromegaly - Complications - Drug Therapy - Pathologyen_US
dc.subject.meshAdulten_US
dc.subject.meshAntineoplastic Agents - Therapeutic Useen_US
dc.subject.meshCephalometryen_US
dc.subject.meshFemaleen_US
dc.subject.meshFollow-Up Studiesen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshOctreotide - Therapeutic Useen_US
dc.subject.meshPolysomnographyen_US
dc.subject.meshSleep Apnea Syndromes - Complications - Drug Therapy - Pathologyen_US
dc.subject.meshSomatostatin - Analogs & Derivativesen_US
dc.subject.meshStatistics, Nonparametricen_US
dc.subject.meshTomography, X-Ray Computeden_US
dc.titleEffect of Sandostatin® LAR® on sleep apnoea in acromegaly: Correlation with computerized tomographic cephalometry and hormonal activityen_US
dc.typeArticleen_US
dc.identifier.emailIp, MSM:msmip@hku.hken_US
dc.identifier.emailTan, KCB:kcbtan@hku.hken_US
dc.identifier.emailLam, KSL:ksllam@hku.hken_US
dc.identifier.authorityIp, MSM=rp00347en_US
dc.identifier.authorityTan, KCB=rp00402en_US
dc.identifier.authorityLam, KSL=rp00343en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1046/j.1365-2265.2001.01358.xen_US
dc.identifier.pmid11678830-
dc.identifier.scopuseid_2-s2.0-0034790831en_US
dc.identifier.hkuros69085-
dc.identifier.hkuros85702-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0034790831&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume55en_US
dc.identifier.issue4en_US
dc.identifier.spage477en_US
dc.identifier.epage483en_US
dc.identifier.isiWOS:000171606700009-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridIp, MSM=7102423259en_US
dc.identifier.scopusauthoridTan, KCB=8082703100en_US
dc.identifier.scopusauthoridPeh, WCG=7101824984en_US
dc.identifier.scopusauthoridLam, KSL=8082870600en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats